Clinical Trials Directory

Trials / Completed

CompletedNCT02002533

Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy

Feasibility, Acceptability and Mechanisms of Brief Behavioral Therapy (BBT) for Sleep Problems During Chemotherapy: A Phase II Randomized Controlled Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
71 (actual)
Sponsor
Gary Morrow · Academic / Other
Sex
Female
Age
21 Years
Healthy volunteers
Not accepted

Summary

This randomized phase II trial studies how well brief behavioral therapy works in improving sleep disorders in patients with stage I-III breast cancer undergoing chemotherapy. Sleep disorder counseling may reduce fatigue and insomnia as well as improve the well-being and quality of life in patients with breast cancer who are undergoing chemotherapy.

Detailed description

PRIMARY OBJECTIVES: I. Determine recruitment rates to the proposed randomized controlled trial (RCT). II. Determine the rate of intervention adherence. III. Determine the feasibility of training National Cancer Institute (NCI) Community Oncology Research Program (NCORP) clinical research staff to successfully deliver the Brief Behavioral Therapy (BBT) intervention. SECONDARY OBJECTIVES: I. Obtain preliminary estimates for the effect of the intervention (compared with control) on insomnia as measured by the Insomnia Severity Index (ISI). II. Obtain preliminary estimates for the effect of the intervention (compared with control) on sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI). III. Obtain preliminary estimates for the effect of the intervention (compared with control) on circadian rhythm as measured by the two-oscillator cosinor parameter estimates based on actigraphy data. IV. Obtain preliminary estimates for the effect of the intervention (compared with control) on heart rate variability (HRV) as measured by the Firstbeat® ambulatory heart-rate monitor (i.e., 1. respiratory sinus arrhythmia-RSA, 2. standard deviation of all normal R-wave to R-wave intervals--SDNN, 3. root mean square of successive differences between adjacent normal R-wave to R-wave intervals--RMSSD, 4. The ratio of low frequency total spectrum power of all NN intervals between .04 to .15 Hertz to high frequency total spectrum power of all NN intervals between .15 to .40 Hertz--LF/HF ratio, and 5. natural log of low frequency total spectrum power of all NN intervals between 0.04 to 0.15Hz.). TERTIARY OBJECTIVES: I. Obtain preliminary estimates for the effect of the intervention (compared with control) on quality of life as measured by the Functional Assessment of Chronic Illness Therapy (FACIT) total score and subscales. II. Obtain preliminary estimates for the effect of the intervention (compared with control) on general mood as measured by the Profile of Mood States (POMS) total score and subscales. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients undergo BBT intervention, comprising insomnia education, stimulus control, discouragement of napping and encouragement of exercise, and sleep compression over two 60 minute face-to-face sessions in weeks 1 and 3 or 4, and four 15 minute telephone sessions in weeks 2, 3, 5, and 6 or 2, 4, 5, and 6. ARM II: Patients undergo Healthy Eating Education (HEAL) comprising nutritional education and suggestions for symptom management over two 60 minute face-to-face sessions in weeks 1 and 2 or 3, and four 15 minute telephone sessions in weeks 2, 3, 5, and 6 or 2, 4, 5, and 6. After completion of study, patients are followed up at 1 month.

Conditions

Interventions

TypeNameDescription
BEHAVIORALBrief Behavioral TherapyUndergo BBT intervention
BEHAVIORALTelephone-Based InterventionUndergo BBT intervention
OTHEREducational InterventionUndergo HEAL
BEHAVIORALTelephone-Based InterventionUndergo HEAL

Timeline

Start date
2014-02-03
Primary completion
2016-12-16
Completion
2016-12-16
First posted
2013-12-06
Last updated
2019-06-05
Results posted
2017-12-02

Locations

6 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02002533. Inclusion in this directory is not an endorsement.